Program
triptorelin
Also written as “Triptorelin embonate 22.5 mg”, “Triptorelin (Decapeptyl®)” and “Decapeptyl® SR 22.5mg”.
Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Ovarian Hyperstimulation Syndrome, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ipsen | 130 open or running | phase 4since Aug 23, 2012 | Dec 21, 2006 | none ahead |
| Debiopharm | 30 open or running | phase 3since Sep 11, 2008 | Sep 11, 2008 | none ahead |
| Foresee Pharmaceuticals | 20 open or running | phase 3since Jan 22, 2025 | Jan 22, 2025 | none ahead |
| AbbVie | 10 open or running | phase 4since Jul 9, 2010 | Jul 9, 2010 | none ahead |
| Pharmatech | 10 open or running | phase 4since May 8, 2012 | May 8, 2012 | none ahead |
Also a collaborator on its studies: qps-holdings-llc and quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Dec 21, 2006.
- Nov 24, 2009Phase 3 study in Prostatic NeoplasmsIpsen · NCT01020448 · 339 enrolled · Belgium, Denmark, France and more
- Jul 9, 2010AbbVie's first study: phase 4 study in Prostatic NeoplasmsNew to AbbVieAbbVie · NCT01161563 · 118 enrolled · United States
- Dec 8, 2010Phase 2 study in Prostatic NeoplasmsIpsen · NCT01257425 · 109 enrolled · Germany
- Jun 14, 2011Phase 2 study in Prostatic NeoplasmsIpsen · NCT01374087 · 32 enrolled · Spain
- Nov 7, 2011Phase 3 study in Puberty, PrecociousDebiopharm · NCT01467882 · 44 enrolled · United States, Chile, Mexico
- May 8, 2012Pharmatech's first study: phase 4 study in Prostatic NeoplasmsNew to PharmatechPharmatech · NCT02749825 · 41 enrolled · United States
- Jul 31, 2012Phase 3 study in Prostatic NeoplasmsDebiopharm · NCT01656161 · 120 enrolled · South Africa
- Aug 23, 2012Phase 4 study in Prostatic NeoplasmsIpsen · NCT01673984 · 27 enrolled · United Kingdom
- Oct 24, 2012Phase 3 study in Prostatic NeoplasmsIpsen · NCT01715129 · 126 enrolled · Bulgaria, France, Latvia and more
- Dec 17, 2012Phase 4 study in Prostatic NeoplasmsIpsen · NCT01753297 · 226 enrolled · China, Russian Federation
- Jan 29, 2021Phase 3 study in Puberty, PrecociousIpsen · NCT04736602 · 32 enrolled · China
- Aug 9, 2021Phase 3 study in Puberty, PrecociousIpsen · NCT05029622 · 66 enrolled · China
- Jun 17, 2022Phase 3 study in Prostatic NeoplasmsIpsen · NCT05458856 · 147 enrolled · Belgium, Czechia, France and more
- Jan 22, 2025Foresee Pharmaceuticals's first studies: 2 phase 3 studies in Prostatic NeoplasmsNew to Foresee PharmaceuticalsForesee Pharmaceuticals · NCT06795191, NCT06795178
TargetBeta
“A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH)”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Goserelinrule | AstraZeneca | phase 4 | 14 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06795191Prostatic Neoplasms | 3 | Withdrawn | Foresee Pharmaceuticals | Nov 30, 2027 | 0 |
| NCT06795178Prostatic Neoplasms | 3 | Withdrawn | Foresee Pharmaceuticals | Dec 31, 2027 | 0 |
| NCT05458856Prostatic Neoplasms · Belgium, Czechia, France and more | 3 | Completed | Ipsen | Jul 8, 2024 | 147 |
| NCT05029622Puberty, Precocious · China | 3 | Completed | Ipsen | Aug 21, 2022 | 66 |
| NCT04736602Puberty, Precocious · China | 3 | Completed | Ipsen | Feb 9, 2022 | 32 |
| NCT01753297Prostatic Neoplasms · China, Russian Federation | 4 | Completed | Ipsen | Sep 9, 2019 | 226 |
| NCT01715129Prostatic Neoplasms · Bulgaria, France, Latvia and more | 3 | Completed | Ipsen | Oct 2013 | 126 |
| NCT01673984Prostatic Neoplasms · United Kingdom | 4 | Terminated | Ipsen | Feb 2014 | 27 |
| NCT01656161Prostatic Neoplasms · South Africa | 3 | Completed | Debiopharm | Aug 2013 | 120 |
| NCT02749825Prostatic Neoplasms · United States | 4 | Terminated | Pharmatech | May 2006 | 41 |
| NCT01467882Puberty, Precocious · United States, Chile, Mexico | 3 | Completed | Debiopharm | Aug 2013 | 44 |
| NCT01374087Prostatic Neoplasms · Spain | 2 | Terminated | Ipsen | Dec 2014 | 32 |
| NCT01257425Prostatic Neoplasms · Germany | 2 | Completed | Ipsen | Feb 2012 | 109 |
| NCT01161563Prostatic Neoplasms · United States | 4 | Completed | AbbVie | Apr 2011 | 118 |
| NCT01020448Prostatic Neoplasms · Belgium, Denmark, France and more | 3 | Completed | Ipsen | Nov 2011 | 339 |
| NCT00909844Puberty, Precocious · France | 3 | Completed | Ipsen | Apr 2015 | 35 |
| NCT00751790Prostatic Neoplasms · South Africa | 3 | Completed | Debiopharm | Aug 2007 | 120 |
| NCT00564850Puberty, Precocious · France | 3 | Completed | Ipsen | Oct 2010 | 37 |
| NCT00444639Prostatic Neoplasms · Netherlands | 2 | Terminated | Ipsen | Feb 2008 | 25 |
| NCT00415246Prostatic Neoplasms · Belgium, France, Latvia and more | 3 | Terminated | Ipsen | 100 |
How it is read
Names in the registry
- “Triptorelin embonate 22.5 mg”, 2 entries
- “Triptorelin (Decapeptyl®)”, 2 entries
- “Decapeptyl® SR 22.5mg”, 1 entry
- “Triptorelin Mesylate”, 1 entry
- “FP-014”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 15 studies
- Puberty, Precocious, 5 studies
- Ovarian Hyperstimulation Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.